Time course of interferon-γ production deficiency after autologous and allogeneic stem cell transplantation for malignancies

H. Hanenberg, D. Dilloo, H. J. Laws, N. Zessack, A. Heyll, S. Burdach

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

While success of autologous bone marrow transplantation (BMT) for malignancies largely depends on the cytotoxicity of the ablative regimen, achievement of relapse-free survival after allogeneic BMT is thought to be enhanced by immunologic effects. We therefore investigated in vivo and in vitro production of interferon-γ (IFN-γ), soluble interleukin-2 (IL-2) receptor α-chain (sCD25), tumor necrosis factor-α (TNF-α), and granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients before and during various time periods up to 2 years after autologous and allogeneic BMT. Cytokine levels were assessed in patient plasma and in supernatants of patient-derived peripheral blood mononuclear cells (PBMNC) cultured for 3 days in the presence of T cell-specific stimulation via CD3 plus IL-2. Our studies show that IFN-γ plasma levels are decreased in autologous graft recipients before and during the first 30 days posttransplant. In allogeneic graft recipients, IFN-γ plasma levels are also decreased during the first 30 days posttransplant, but otherwise are comparable to normal control (NC) values. In vitro stimulated PBMNC from autologous graft recipients also exhibit an IFN-γ production defect before and during the first 30 days posttransplant. In contrast, before and up to 30 days after allogeneic BMT, stimulated IFN-γ production is comparable to NC values but then gradually decreases, reaching its trough levels at between 61 and 180 days post-BMT. The IFN-γ production defects in both patient groups seem to be specific, as sCD25, TNF-α and GM-CSF production in stimulated PBMNC is normal or even enhanced at any time after autologous or allogeneic BMT. Deficient IFN-γ production in patient-derived PBMNC does not correlate with variation in monocyte, T cell, or natural killer (NK) cell numbers during the posttransplantation course.

Original languageEnglish (US)
Pages (from-to)1543-1552
Number of pages10
JournalExperimental Hematology
Volume23
Issue number14
StatePublished - 1995
Externally publishedYes

Fingerprint

Stem Cell Transplantation
Interferons
Bone Marrow Transplantation
Homologous Transplantation
Blood Cells
Neoplasms
Granulocyte-Macrophage Colony-Stimulating Factor
Transplants
Reference Values
Tumor Necrosis Factor-alpha
T-Lymphocytes
Autologous Transplantation
Interleukin-2 Receptors
Natural Killer Cells
Interleukin-2
Monocytes
Cell Count
Cytokines
Recurrence
Survival

Keywords

  • Allogeneic transplantation
  • Autologous transplantation
  • Cytokines
  • Interferon-γ deficiency

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Genetics
  • Hematology
  • Oncology
  • Transplantation

Cite this

Hanenberg, H., Dilloo, D., Laws, H. J., Zessack, N., Heyll, A., & Burdach, S. (1995). Time course of interferon-γ production deficiency after autologous and allogeneic stem cell transplantation for malignancies. Experimental Hematology, 23(14), 1543-1552.

Time course of interferon-γ production deficiency after autologous and allogeneic stem cell transplantation for malignancies. / Hanenberg, H.; Dilloo, D.; Laws, H. J.; Zessack, N.; Heyll, A.; Burdach, S.

In: Experimental Hematology, Vol. 23, No. 14, 1995, p. 1543-1552.

Research output: Contribution to journalArticle

Hanenberg, H, Dilloo, D, Laws, HJ, Zessack, N, Heyll, A & Burdach, S 1995, 'Time course of interferon-γ production deficiency after autologous and allogeneic stem cell transplantation for malignancies', Experimental Hematology, vol. 23, no. 14, pp. 1543-1552.
Hanenberg, H. ; Dilloo, D. ; Laws, H. J. ; Zessack, N. ; Heyll, A. ; Burdach, S. / Time course of interferon-γ production deficiency after autologous and allogeneic stem cell transplantation for malignancies. In: Experimental Hematology. 1995 ; Vol. 23, No. 14. pp. 1543-1552.
@article{20a4e4d7a4c4485eaeb64c022cc40c2d,
title = "Time course of interferon-γ production deficiency after autologous and allogeneic stem cell transplantation for malignancies",
abstract = "While success of autologous bone marrow transplantation (BMT) for malignancies largely depends on the cytotoxicity of the ablative regimen, achievement of relapse-free survival after allogeneic BMT is thought to be enhanced by immunologic effects. We therefore investigated in vivo and in vitro production of interferon-γ (IFN-γ), soluble interleukin-2 (IL-2) receptor α-chain (sCD25), tumor necrosis factor-α (TNF-α), and granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients before and during various time periods up to 2 years after autologous and allogeneic BMT. Cytokine levels were assessed in patient plasma and in supernatants of patient-derived peripheral blood mononuclear cells (PBMNC) cultured for 3 days in the presence of T cell-specific stimulation via CD3 plus IL-2. Our studies show that IFN-γ plasma levels are decreased in autologous graft recipients before and during the first 30 days posttransplant. In allogeneic graft recipients, IFN-γ plasma levels are also decreased during the first 30 days posttransplant, but otherwise are comparable to normal control (NC) values. In vitro stimulated PBMNC from autologous graft recipients also exhibit an IFN-γ production defect before and during the first 30 days posttransplant. In contrast, before and up to 30 days after allogeneic BMT, stimulated IFN-γ production is comparable to NC values but then gradually decreases, reaching its trough levels at between 61 and 180 days post-BMT. The IFN-γ production defects in both patient groups seem to be specific, as sCD25, TNF-α and GM-CSF production in stimulated PBMNC is normal or even enhanced at any time after autologous or allogeneic BMT. Deficient IFN-γ production in patient-derived PBMNC does not correlate with variation in monocyte, T cell, or natural killer (NK) cell numbers during the posttransplantation course.",
keywords = "Allogeneic transplantation, Autologous transplantation, Cytokines, Interferon-γ deficiency",
author = "H. Hanenberg and D. Dilloo and Laws, {H. J.} and N. Zessack and A. Heyll and S. Burdach",
year = "1995",
language = "English (US)",
volume = "23",
pages = "1543--1552",
journal = "Experimental Hematology",
issn = "0301-472X",
publisher = "Elsevier Inc.",
number = "14",

}

TY - JOUR

T1 - Time course of interferon-γ production deficiency after autologous and allogeneic stem cell transplantation for malignancies

AU - Hanenberg, H.

AU - Dilloo, D.

AU - Laws, H. J.

AU - Zessack, N.

AU - Heyll, A.

AU - Burdach, S.

PY - 1995

Y1 - 1995

N2 - While success of autologous bone marrow transplantation (BMT) for malignancies largely depends on the cytotoxicity of the ablative regimen, achievement of relapse-free survival after allogeneic BMT is thought to be enhanced by immunologic effects. We therefore investigated in vivo and in vitro production of interferon-γ (IFN-γ), soluble interleukin-2 (IL-2) receptor α-chain (sCD25), tumor necrosis factor-α (TNF-α), and granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients before and during various time periods up to 2 years after autologous and allogeneic BMT. Cytokine levels were assessed in patient plasma and in supernatants of patient-derived peripheral blood mononuclear cells (PBMNC) cultured for 3 days in the presence of T cell-specific stimulation via CD3 plus IL-2. Our studies show that IFN-γ plasma levels are decreased in autologous graft recipients before and during the first 30 days posttransplant. In allogeneic graft recipients, IFN-γ plasma levels are also decreased during the first 30 days posttransplant, but otherwise are comparable to normal control (NC) values. In vitro stimulated PBMNC from autologous graft recipients also exhibit an IFN-γ production defect before and during the first 30 days posttransplant. In contrast, before and up to 30 days after allogeneic BMT, stimulated IFN-γ production is comparable to NC values but then gradually decreases, reaching its trough levels at between 61 and 180 days post-BMT. The IFN-γ production defects in both patient groups seem to be specific, as sCD25, TNF-α and GM-CSF production in stimulated PBMNC is normal or even enhanced at any time after autologous or allogeneic BMT. Deficient IFN-γ production in patient-derived PBMNC does not correlate with variation in monocyte, T cell, or natural killer (NK) cell numbers during the posttransplantation course.

AB - While success of autologous bone marrow transplantation (BMT) for malignancies largely depends on the cytotoxicity of the ablative regimen, achievement of relapse-free survival after allogeneic BMT is thought to be enhanced by immunologic effects. We therefore investigated in vivo and in vitro production of interferon-γ (IFN-γ), soluble interleukin-2 (IL-2) receptor α-chain (sCD25), tumor necrosis factor-α (TNF-α), and granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients before and during various time periods up to 2 years after autologous and allogeneic BMT. Cytokine levels were assessed in patient plasma and in supernatants of patient-derived peripheral blood mononuclear cells (PBMNC) cultured for 3 days in the presence of T cell-specific stimulation via CD3 plus IL-2. Our studies show that IFN-γ plasma levels are decreased in autologous graft recipients before and during the first 30 days posttransplant. In allogeneic graft recipients, IFN-γ plasma levels are also decreased during the first 30 days posttransplant, but otherwise are comparable to normal control (NC) values. In vitro stimulated PBMNC from autologous graft recipients also exhibit an IFN-γ production defect before and during the first 30 days posttransplant. In contrast, before and up to 30 days after allogeneic BMT, stimulated IFN-γ production is comparable to NC values but then gradually decreases, reaching its trough levels at between 61 and 180 days post-BMT. The IFN-γ production defects in both patient groups seem to be specific, as sCD25, TNF-α and GM-CSF production in stimulated PBMNC is normal or even enhanced at any time after autologous or allogeneic BMT. Deficient IFN-γ production in patient-derived PBMNC does not correlate with variation in monocyte, T cell, or natural killer (NK) cell numbers during the posttransplantation course.

KW - Allogeneic transplantation

KW - Autologous transplantation

KW - Cytokines

KW - Interferon-γ deficiency

UR - http://www.scopus.com/inward/record.url?scp=0029618805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029618805&partnerID=8YFLogxK

M3 - Article

VL - 23

SP - 1543

EP - 1552

JO - Experimental Hematology

JF - Experimental Hematology

SN - 0301-472X

IS - 14

ER -